A phase I, open‐label study evaluating the safety and efficacy of adoptive transfer of autologous NY‐ESO‐1 CD8‐TCR engineered T cells and NY‐ESO‐1 CD4‐TCR engineered HSCs after a myeloablative conditioning regimen, with administration of IL‐2 in patients with recurrent or treatment refractory ovarian, fallopian tube or primary peritoneal cancer. This evidence concerns the gene IL2 and peritoneum cancer.